37 Ken Fisher Myriad Genetics Trades
Ken Fisher acquired 905 Thousand Myriad Genetics shares worth $3.52 Million. That's 0.00% of their equity portfolio (523rd largest holding). The first Myriad Genetics trade was made in Q4 2014. Since then Ken Fisher bought shares 25 more times and sold shares on eleven occasions. The investor's estimated purchase price is $21.6 Million, resulting in a loss of 84%.
News about Myriad Genetics, Inc. and Ken Fisher
Genomic Biomarker Market Size, Key Opportunities, Strategic Assessment, Strong Revenue | Oprating Vendors: Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigen
The documented report on Global Genomic Biomarker Market by Reports Globe aims to offer an organized and methodical strategy for important aspects that have ...
Global Genomic Biomarkers Market Trends, Growth, Size, Segmentation, Future Demands, Latest Innovation 2020-2026|| Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc, Eurofins Scientific, QIAGEN
This Genomic Biomarkers concerning the Genomic Biomarkers market has been published to assist the user in understanding the market as a whole, its definition...
Global Genetic Testing Market Outlook to 2022 Featuring Abbott Laboratories, Roche Diagnostics, Myriad Genetics, Thermo Fisher Scientific, Hologic, Cepheid, Agilent Technologies, and QIAGEN
DUBLIN, Dec. 16, 2020 /PRNewswire/ -- The "Global Genetic Testing Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering. "Global Ge...
Global Clinical Oncology Next Generation Sequencing Market Vigorous Growth 2020-2027 | Top Companies-F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Thermo Fisher Scientific, Myriad Genetics Inc., BGI, Perkin Elmer, Inc
“Global Clinical Oncology Next Generation Sequencing Market- Industry Trends and Forecast to 2027” Worldwide Industry Size, Offer and trends analysis during ...